Merck & Company Inc Total Assets
Merck & Company Inc total assets. Based on the latest financial reports, Merck & Company Inc (MRK) holds total assets worth $129.80 Billion USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see MRK stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Merck & Company Inc (1985–2025)
Total assets of Merck & Company Inc from 1985 to 2025. This chart illustrates how Merck & Company Inc's total assets have evolved over time, based on quarterly financial data. See MRK live share price for real-time trading data and today's change.
Merck & Company Inc - Asset Composition Analysis
Merck & Company Inc Total Assets Breakdown (December 2025)
Merck & Company Inc total assets breakdown as of December 2025. Merck & Company Inc's total assets of $129.80 Billion consist of 31.8% current assets and 68.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $14.56 Billion | 10.6% |
| Accounts Receivable | $12.68 Billion | 9.3% |
| Inventory | $6.66 Billion | 4.9% |
| Property, Plant & Equipment | $26.82 Billion | 19.6% |
| Intangible Assets | $26.68 Billion | 19.5% |
| Goodwill | $21.58 Billion | 15.8% |
Asset Composition Trend (1985–2025)
This chart illustrates how Merck & Company Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Merck & Company Inc working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Merck & Company Inc's current assets represent 31.8% of total assets in 2025, a decrease from 47.1% in 1985.
- Cash Position: Cash and equivalents constituted 10.6% of total assets in 2025, down from 17.2% in 1985.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 34.0% of total assets, an increase from 1.0% in 1985.
- Asset Diversification: The largest asset category is property, plant & equipment at 19.6% of total assets.
Merck & Company Inc Competitors by Total Assets
Key competitors of Merck & Company Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
AstraZeneca PLC
NASDAQ:AZN
|
USA | $114.02 Billion |
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$201.13 Billion |
|
Novartis AG
MX:NVSN
|
Mexico | MX$118.53 Billion |
|
Pfizer Inc
NYSE:PFE
|
USA | $201.13 Billion |
|
Novo Nordisk A/S
CO:NOVO-B
|
Denmark | Dkr542.90 Billion |
|
Zhejiang Int'L Group Co Ltd
SHE:000411
|
China | CN¥17.31 Billion |
|
SANOFI CONS HEALTHC IND L
NSE:SANOFICONR
|
India | Rs5.47 Billion |
|
AstraZeneca PLC
F:ZEGA
|
Germany | €114.46 Billion |
Merck & Company Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.32 | 1.42 | 1.31 |
| Quick Ratio | 1.10 | 1.17 | 0.97 |
| Cash Ratio | 0.00 | 0.31 | 0.42 |
| Working Capital | $8.95 Billion | $11.03 Billion | $7.33 Billion |
Merck & Company Inc - Advanced Valuation Insights
This section examines the relationship between Merck & Company Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.92 |
| Latest Market Cap to Assets Ratio | 2.32 |
| Asset Growth Rate (YoY) | 16.9% |
| Total Assets | $136.87 Billion |
| Market Capitalization | $316.95 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Merck & Company Inc's assets at a significant premium (2.32x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Merck & Company Inc's assets grew by 16.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Merck & Company Inc (1985–2025)
The table below shows the annual total assets of Merck & Company Inc from 1985 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $136.87 Billion | +16.87% |
| 2024-12-31 | $117.11 Billion | +9.78% |
| 2023-12-31 | $106.67 Billion | -2.28% |
| 2022-12-31 | $109.16 Billion | +3.28% |
| 2021-12-31 | $105.69 Billion | +15.40% |
| 2020-12-31 | $91.59 Billion | +8.52% |
| 2019-12-31 | $84.40 Billion | +2.13% |
| 2018-12-31 | $82.64 Billion | -5.96% |
| 2017-12-31 | $87.87 Billion | -7.87% |
| 2016-12-31 | $95.38 Billion | -6.20% |
| 2015-12-31 | $101.68 Billion | +3.58% |
| 2014-12-31 | $98.17 Billion | -7.08% |
| 2013-12-31 | $105.64 Billion | -0.46% |
| 2012-12-31 | $106.13 Billion | +0.96% |
| 2011-12-31 | $105.13 Billion | -0.62% |
| 2010-12-31 | $105.78 Billion | -5.82% |
| 2009-12-31 | $112.31 Billion | +137.98% |
| 2008-12-31 | $47.20 Billion | -2.39% |
| 2007-12-31 | $48.35 Billion | +8.48% |
| 2006-12-31 | $44.57 Billion | -0.62% |
| 2005-12-31 | $44.85 Billion | +5.34% |
| 2004-12-31 | $42.57 Billion | +4.89% |
| 2003-12-31 | $40.59 Billion | -14.66% |
| 2002-12-31 | $47.56 Billion | +8.04% |
| 2001-12-31 | $44.02 Billion | +10.30% |
| 2000-12-31 | $39.91 Billion | +12.00% |
| 1999-12-31 | $35.63 Billion | +11.87% |
| 1998-12-31 | $31.85 Billion | +23.77% |
| 1997-12-31 | $25.74 Billion | +5.94% |
| 1996-12-31 | $24.29 Billion | +1.94% |
| 1995-12-31 | $23.83 Billion | +9.04% |
| 1994-12-31 | $21.86 Billion | +9.68% |
| 1993-12-31 | $19.93 Billion | +79.75% |
| 1992-12-31 | $11.09 Billion | +16.71% |
| 1991-12-31 | $9.50 Billion | +18.29% |
| 1990-12-31 | $8.03 Billion | +18.84% |
| 1989-12-31 | $6.76 Billion | +10.27% |
| 1988-12-31 | $6.13 Billion | +7.88% |
| 1987-12-31 | $5.68 Billion | +11.26% |
| 1986-12-31 | $5.11 Billion | +4.14% |
| 1985-12-31 | $4.90 Billion | -- |
About Merck & Company Inc
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, a… Read more